Aims/Background:
Ovariectomy (OVX)-induced murine model is widely used for postmenopausal
osteoporosis study. Our current study was conducted to systematically review and essentially
quantified the bone mass enhancing effect of puerarin on treating OVX-induced postmenopausal
osteoporosis in murine model.
Methods:
Literatures from PUBMED, EMBASE, and CNKI were involved in our searching strategy
by limited the inception date to January 9th, 2019. Moreover, the enhancing effect of puerarin on bone
mass compared to OVX-induced rats is evaluated by four independent reviewers. Finally, all the data
were extracted, quantified and analyzed via RevMan, besides that in our current review study, we assessed
the methodological quality for each involved study.
Results:
Based on the searching strategy, eight randomization studies were finally included in current
meta-analysis and systematic review. According to the data analysis by RevMan, puerarin could improve
bone mineral density (BMD); (eight studies, n=203; weighted mean difference, 0.05; 95% CI,
0.03-0.07; P<0.0001) using a random-effects model. There is no significant difference between puerarin
and estrogen (seven studies, n=184; weighted mean difference, 0.00; 95% CI, -0.01 to 0.00;
P=0.30).
Conclusions:
Puerarin showed upregulating effects on bone mass in OVX-induced postmenopausal
osteoporosis in murine model. More studies of the effect of puerarin on bone density in OVX animals
are needed.
The Standardized BHH10 Extract, a Combination of
Astragalus membranaceus
,
Cinnamomum cassia
, and
Phellodendron amurense
, Reverses Bone Mass and Metabolism in a Rat Model of Postmenopausal Osteoporosis